{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:10:25Z","timestamp":1777972225746,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2021-NR059785"],"award-info":[{"award-number":["RS-2021-NR059785"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2024-00438143"],"award-info":[{"award-number":["RS-2024-00438143"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-KH137294"],"award-info":[{"award-number":["RS-2023-KH137294"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.nucmedbio.2025.109569","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:32:40Z","timestamp":1760139160000},"page":"109569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Preclinical evaluation and dosimetry of [64Cu\/67Cu]Cu-NGUL for PSMA-targeted prostate cancer theranostics"],"prefix":"10.1016","volume":"150-151","author":[{"given":"Hye Yeon","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minseok","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem Ahmed","family":"Lodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran Ji","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azmal Kabir","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyo Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwangil","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kweon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Min","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2025.109569_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA\u2013PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0015","first-page":"4363","article-title":"Screening for prostate cancer: an update","volume":"15","author":"Shariat","year":"2008","journal-title":"Can J Urol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0020","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1021\/jm401921j","article-title":"64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer","volume":"57","author":"Banerjee","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0025","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","author":"Perner","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2014.05.035","article-title":"Prostate cancer relevant antigens and enzymes for targeted drug delivery","volume":"187","author":"Barve","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.117.191874","article-title":"Why targeting PSMA is a game changer in the management of prostate cancer","volume":"59","author":"Donin","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0045","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.3390\/cancers13215360","article-title":"Molecular imaging in primary staging of prostate cancer patients: current aspects and future trends","volume":"13","author":"Manafi-Farid","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0050","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/pharmaceutics14051098","article-title":"Design, synthesis, and evaluation of linker-optimised PSMA-targeting radioligands","volume":"14","author":"Lundmark","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0055","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","article-title":"Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer","volume":"69","author":"Hillier","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.e16007","article-title":"Antiandrogen modulation of prostate-specific membrane antigen (PSMA): dynamics and synergy with PSMA-targeted therapy","volume":"31","author":"DiPippo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0065","first-page":"14","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals-Base"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0070","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","article-title":"68Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging","volume":"26","author":"Derlin","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0075","article-title":"A pilot study of 68Ga-PSMA-617 PET\/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma","volume":"63","author":"Wang","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0080","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.bmc.2018.04.014","article-title":"Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting","volume":"26","author":"Moon","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0085","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2967\/jnumed.120.258434","article-title":"Head-to-head comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study","volume":"62","author":"Suh","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0090","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3348\/kjr.2022.0176","article-title":"Phase I clinical trial of prostate-specific membrane antigen-targeting 68Ga-NGUL PET\/CT in healthy volunteers and patients with prostate cancer","volume":"23","author":"Suh","year":"2022","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0095","doi-asserted-by":"crossref","first-page":"12550","DOI":"10.1021\/jacs.7b05937","article-title":"Evaluation of 64Cu-based radiopharmaceuticals that target a\u03b2 peptide aggregates as diagnostic tools for Alzheimer\u2019s disease","volume":"139","author":"Bandara","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0100","first-page":"379","article-title":"Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research","volume":"24","author":"Anderson","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0105","first-page":"29","article-title":"64Cu-labeled melanin nanoparticles for PET\/CT and radionuclide therapy of tumor","author":"Zhou","year":"2020","journal-title":"Nanomed-Nanotechnol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0110","first-page":"18","article-title":"64Cu-based radiopharmaceuticals in molecular imaging","author":"Zhou","year":"2019","journal-title":"Technol Cancer Res T"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0115","first-page":"6","article-title":"Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of \u03b1MSH peptide","author":"Yang","year":"2021","journal-title":"Ejnmmi Radiopharm Ch"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0120","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2967\/jnumed.112.118539","article-title":"The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer","volume":"54","author":"Guo","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00775-015-1318-7","article-title":"Promising bifunctional chelators for copper 64-PET imaging: practical 64Cu radiolabeling and high in vitro and in vivo complex stability","volume":"21","author":"Wu","year":"2016","journal-title":"J Biol Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0130","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1021\/acs.molpharmaceut.8b00712","article-title":"Design and preclinical evaluation of an albumin-binding PSMA ligand for 64Cu-based PET imaging","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0135","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.122.264586","article-title":"64Cu treatment planning and 67Cu therapy with radiolabeled [64Cu\/67Cu]MeCOSar-octreotate in subjects with unresectable multifocal meningioma: initial results for human imaging, safety, biodistribution, and radiation dosimetry","volume":"64","author":"Bailey","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0140","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1021\/acs.molpharmaceut.0c00060","article-title":"Preclinical evaluation of a high-affinity Sarcophagine-containing PSMA ligand for 64Cu\/67Cu-based theranostics in prostate cancer","volume":"17","author":"Kelly","year":"2020","journal-title":"Mol Pharm"},{"issue":"39","key":"10.1016\/j.nucmedbio.2025.109569_bb0145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-011-2003-x","article-title":"Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET\/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy","volume":"I","author":"Sainz-Esteban","year":"2012","journal-title":"Eur J Nucl Med Mol"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1162\/153535003322556877","article-title":"AMIDE: a free software tool for multimodality medical image analysis","volume":"2","author":"Loening","year":"2003","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0155","first-page":"247","article-title":"Letter: radiation dosimetry of 131-I-19-iodocholesterol: the pitfalls of using tissue concentration data","volume":"16","author":"Blau","year":"1975","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0160","doi-asserted-by":"crossref","first-page":"20621","DOI":"10.1021\/acs.inorgchem.3c00621","article-title":"Is smaller better? Cu2+\/Cu+ coordination chemistry and Copper-64 radiochemical investigation of a 1,4,7-triazacyclononane-based sulfur-rich chelator","volume":"62","author":"Tosato","year":"2023","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128044","article-title":"Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): a comparison of urea and thiourea derivatives","volume":"42","author":"Young","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0170","doi-asserted-by":"crossref","first-page":"12296","DOI":"10.1021\/acs.jmedchem.4c02626","article-title":"Prodrugs targeting prostate-specific membrane antigen against prostate cancer","volume":"68","author":"Liolios","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0175","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","article-title":"State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET","volume":"32","author":"Chomet","year":"2021","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnumed.119.229054","article-title":"Development of novel PSMA ligands for imaging and therapy with copper isotopes","volume":"61","author":"Carlos Dos Santos","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0190","first-page":"417","article-title":"The feasibility of 64Cu-PSMA I&T PET for prostate cancer","volume":"37","author":"Lee","year":"2022","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0195","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.7150\/thno.13448","article-title":"Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals","volume":"6","author":"Wustemann","year":"2016","journal-title":"Theranostics"},{"issue":"46","key":"10.1016\/j.nucmedbio.2025.109569_bb0200","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","article-title":"177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy","author":"Banerjee","year":"2019","journal-title":"Eur J Nucl Med Mol I"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41181-024-00237-3","article-title":"A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [68Ga]Ga-PSMA-11","volume":"9","author":"Huang","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0210","first-page":"277","article-title":"64Cu-PSMA-617 PET\/CT imaging of prostate adenocarcinoma: first in-human studies","volume":"31","author":"Grubm\u00fcller","year":"2016","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2025.109569_bb0215","first-page":"15","article-title":"An albumin-binding PSMA ligand with higher tumor accumulation for PET imaging of prostate cancer","author":"Ren","year":"2022","journal-title":"Pharmaceuticals-Base"},{"issue":"43","key":"10.1016\/j.nucmedbio.2025.109569_bb0220","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","article-title":"Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing","volume":"I","author":"Afshar-Oromieh","year":"2016","journal-title":"Eur J Nucl Med Mol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125005785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125005785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:06:41Z","timestamp":1764346001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805125005785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"alternative-id":["S0969805125005785"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109569","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation and dosimetry of [64Cu\/67Cu]Cu-NGUL for PSMA-targeted prostate cancer theranostics","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109569"}}